Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients

Abstract EN

Insertion of central venous port (CVP) catheter in the cancer population is associated with increased incidence of venous thromboembolic events (VTE).

However, trials have shown limited benefit of antithrombotic treatment to prevent catheter-related venous thrombosis.

This prospective observational cohort study was designed to assess the incidence of VTE closely related to CVP implantation in patients with cancer and undergoing chemotherapy, and to identify a high risk subgroup of patients.

Between February 2006 and December 2011, 1097 consecutive cancer patients with first CVP implantation were included.

Catheter-related VTE were defined as deep venous thrombosis in the arm, with or without pulmonary embolism (PE), or isolated PE.

The incidence of CVP-associated VTE was 5.9% (IC95 4.4–7.3%) at 3 months, and 11.3% (IC95 9.4–13.2%) at 12 months.

The incidence of any VTE was 7.6% (IC95 6.0–9.3%) at 3 months, and 15.3% (IC95 13.1–17.6%) at 12 months.

High Khorana risk score and lung cancer were significant predictors of 3 month VTE.

In conclusion, this large cohort study of patients with first CVP catheter implantation confirms the high incidence of VTE associated with the CVP implantation and allow identifying high risk patients who may benefit from thromboprophylaxis.